TY  - JOUR
AU  - Bermejo-Pareja, Félix
AU  - Ser, Teodoro del
AU  - Valentí, Meritxell
AU  - Fuente del Rey, Mónica de la
AU  - Bartolomé, Fernando
AU  - Carro, Eva
PY  - 2020
DO  - 10.1002/alz.12107
SN  - 1552-5260, ESSN 1552-5279
UR  - https://hdl.handle.net/20.500.14352/6594
T2  - Alzheimer's & Dementia
AB  - Objective: We aim to explain why salivary lactoferrin (Lf) levels are reduced in patients suffering mild cognitive impairment (MCI) and sporadic Alzheimer’s disease (sAD).1 We also will discuss if such Lf decrease could be due to a downregulation of...
LA  - eng
M2  - 1196
PB  - Wiley
KW  - Alzheimer’s disease
KW  - Amyloid
KW  - Biomarkers
KW  - Brain-immunity interactions
KW  - Hypothalamus
KW  - Immunity
KW  - Lactoferrin
KW  - Saliva
TI  - Salivary lactoferrin as biomarker for Alzheimer’s disease:brain-immunity interactions
TY  - journal article
VL  - 16
ER  -